TB/FLU-01L

Phase of Development

No longer in development

Vaccine Platform

Viral Vector

Candidate Overview

Replication-deficient recombinant influenza virus A expressing ESAT-6 antigen.

Sponsor / Lead Developer: Research Institute for Biological Safety Problems (RIBSP)

Development partner(s): Smorodintsev Research Institute of Influenza (SRII)

Clinical Trials

COMPLETED TRIALS
Registry NumberNCT06873282
Clinical Trial PhasePhase 2a
Clinical Trial SponsorResearch Institute of Influenza
Primary endpoint(s) for this clinical trialImmunogenicity
Target population(s) for clinical trialAdults
_________________________
Registry NumberNCT05945498
Clinical Trial PhasePhase 1
Clinical Trial SponsorResearch Institute of Influenza
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialAdults

Source: Vaccine sponsor; ClinicalTrials.gov registry; Online search

Date Updated/Reviewed: 01-Jul-2022